TYMS and non-small cell lung carcinoma: TS is targeted by the anti-folate drug pemetrexed, and its overexpression has been proposed to determine chemoresistance.16 For in vitro validation, we established shRNA-mediated TS knockdown in two NSCLC cell lines and observed a significant increase in pemetrexed sensitivity (Fig. 1e, f).